Report contents
Industry landscape
Where the company competes: one US installed base, a long tail abroad
Intuitive Surgical makes robotically controlled instruments for soft-tissue surgery. Its da Vinci systems are capital equipment bought by hospitals; each operation then consumes single-use instruments and accessories, and most customers also buy service contracts. That shape matters more than the system price. A placement is a leading indicator, but the revenue engine is procedure volume, because instruments, accessories and service generate the bulk of the company's revenue. Upstream, Intuitive buys optics, precision mechanisms, electronics and instrument components from a specialized supplier base. Downstream sit hospital systems, surgeons, group purchasing organizations and, increasingly, ambulatory surgery centers. Intuitive reported about $10.06 billion of revenue in fiscal 2025, according to an estimate from Precedence Research.
The core market is precise enough to name: robotic-assisted minimally invasive soft-tissue surgery, concentrated in urology, gynecology, thoracic and general procedures where a surgeon operates through small ports rather than a large incision. Within that, Intuitive's profit center is the US hospital market, where it has sold systems since the early 2000s and where the installed base, surgeon familiarity and instrument reordering are deepest.
Geography sets the competitive rules here, and it splits the market in two. Approval, reimbursement and pricing are decided country by country, so this is not one global arena with one share number. The US is a single large market with a single regulator, and Intuitive's position there is the one that pays. China is a separate contest. Oppenheimer analysts wrote in August 2026 that the meaningful challenge will come outside the US, from domestic Chinese systems such as Medbot, Kangduo and Toumai, and Needham analysts made the same point after the Society of Robotic Surgery meeting, arguing that local vendors could take significant share in the developing world.
Market structure: concentrated at the top, crowded at the bottom. Precedence Research estimates Intuitive holds more than 60% of robotic-assisted soft-tissue surgery, a figure that reflects a market with one scaled incumbent and a set of challengers that have only recently cleared US regulation.
| Company | System | US status | Main arena |
|---|---|---|---|
| Intuitive Surgical | da Vinci 5, da Vinci Xi | Marketed, incumbent | US, Japan, Europe, China |
| Medtronic | Hugo | FDA cleared December 2025; seeking broader indications | US, emerging markets |
| Johnson & Johnson | Ottava | FDA de novo authorization, reported August 2026 | US, global |
| MicroPort MedBot, Kangduo, Toumai | various | China home market | China |
The count of entrants cuts both ways. Needham's team counted 36 companies with competing soft-tissue robots worldwide, which sounds like weak barriers. At the top, though, the leaders still fit on one hand, and only two large medtech firms have cleared the US regulator with a soft-tissue system. The practical reading is that entry is cheap on paper and expensive in practice: a hospital must absorb the capital cost, retrain surgeons who already know a da Vinci console, and accept whatever clinical and reimbursement record a new system has built. That makes US barriers high and Chinese barriers lower, where domestic vendors compete on price and local standing against a foreign incumbent.
The challengers' early US experience suggests the barrier is workflow, not just approval. Oppenheimer's field checks found that Ottava puts four arms into a standard operating table, which requires arm deployment in a non-sterile setting after the patient is positioned and re-sterilization when bodily fluid reaches the table; they also found Hugo occupies more floor space than da Vinci, though Medtronic argues its modular design covers more quadrants. Those are the observations of analysts who rate the stock Outperform, so treat them as one side's field notes, not settled fact. The same team concluded US competition is not yet a factor in Intuitive's growth.
What the numbers would have to show. BTIG analysts put US da Vinci procedure growth at about 12% in the second quarter of 2026, and their survey work found little sign of share erosion. Procedure growth is the right thing to watch, because installed-base share can look stable for years while utilization per system slips. If US procedure growth decelerates toward single digits while Hugo and Ottava placements accumulate, that would be the first hard evidence of share loss; so far the evidence only shows slower growth, not a shift in share. Two other variables could reprice the arena. Oppenheimer flags ambulatory surgery centers as a tactical challenge, since a cheaper, modular system may fit their economics better than a full da Vinci suite. Baird notes that expiring Affordable Care Act insurance subsidies cloud procedure demand. Neither changes who holds the installed base today, but both affect how much of it gets used.
Competitive advantage
Does the company have a moat? Yes, a strong one built on surgeon habit
Moat: Strong. Intuitive Surgical sells a robot to a hospital and then sells the instruments each operation consumes. Two tests decide whether that arrangement is protected: does the market stay concentrated, and does the leader keep earning above its cost of capital? Both pass, with a caveat on each that keeps this from being a clean case.
Market position: No. 1 by a wide margin, on a trend that is inferred
Intuitive ranks first in robotic-assisted soft-tissue surgery. Precedence Research estimates its share at more than 60%, and the two credible US entrants cleared the FDA only in the past year. On the concentration test, this is a market with one scaled incumbent and a set of challengers still early in commercialization. Market position: Strong.
The five-year trend is harder to document than the level. No published source tracks annual share in this niche, so the checkable proxies are procedure growth, revenue growth and the timing of rival approvals. All three point to stability. Revenue rose 20.6% to $10.07 billion in fiscal 2025 and 20.7% year over year in the first half of fiscal 2026. Real share loss would show up as procedure growth stalling on a growing installed base, and it has not.
Greenwald's rule of thumb holds that a five-year share swing of more than 5 percentage points implies no meaningful barrier, while a move under 2 points implies a strong one. Intuitive sits well inside the stable band on the evidence available, but the annual series needed to apply the test precisely is not published, which is why this dimension falls short of the top rating. Stability: Fairly Strong.
Profitability: above the no-moat band, short of the best
Intuitive does not report ROIC. An estimate from the reported figures: operating income of $2.94 billion in fiscal 2025, taxed at the 13% effective rate, gives about $2.56 billion of after-tax operating profit. Invested capital, taken as equity of $17.82 billion less cash of $3.37 billion plus $40 million of borrowings, is roughly $14.5 billion. That puts after-tax ROIC near 18%; leave the cash in the denominator and it falls to about 14%.
Both readings land at the low end of the 15%-25% band that marks a clear advantage, and far above the 6%-8% band that signals none. ROE carries the same distortion. The five-year average is about 15%, weighed down by a debt-free balance sheet whose equity is roughly one-fifth cash. The operating business earns more than the ratios show, because customers, not lenders, fund the working capital.
Margins: wide, mildly compressed and hard to benchmark
| Fiscal year | Revenue (USD bn) | Gross margin (%) | Operating margin (%) | Net margin (%) | ROE (%) | FCF (USD bn) |
|---|---|---|---|---|---|---|
| 2021 | 5.71 | 69.3 | 31.9 | 29.9 | 15.7 | 1.74 |
| 2022 | 6.22 | 67.4 | 25.4 | 21.3 | 11.5 | 0.96 |
| 2023 | 7.12 | 66.4 | 24.9 | 25.2 | 14.8 | 0.75 |
| 2024 | 8.35 | 67.5 | 28.1 | 27.8 | 15.6 | 1.30 |
| 2025 | 10.07 | 66.0 | 29.2 | 28.4 | 16.7 | 2.49 |
Operating margin, fiscal 2025 net margin and fiscal 2025 ROE are computed from reported figures; the rest are as reported.
Gross margin slipped about three points between fiscal 2021 and fiscal 2025. The company's disclosures do not decompose that move among pricing, product mix and manufacturing cost, so the cause stays open. Fiscal 2022 is the sharper break: operating income fell 13% even as revenue rose 9%, and the reported figures do not explain why. What the table does show is that a 66% gross margin held through a stretch of heavy system placement, the lower-margin part of the model, and that net margin recovered to about 28%.
No clean peer comparison exists. Medtronic and Johnson & Johnson are diversified groups several times Intuitive's size, and neither reports robotic-surgery margins separately, so their consolidated figures say little about this contest. The visible difference is scale inside the niche. Margins: Strong.
Overall rating: Strong, on persistence more than level
Moat rating: Strong. Both core tests pass. Share is above 60% and has not visibly eroded, and an after-tax ROIC near 18% on a debt-free balance sheet clears any plausible cost of capital by a wide margin. The weak half is measurement: the share series is thin, and the return figures are dragged down by a cash pile that earns little. A stricter reading would stop at Fairly Strong.
What would change the assessment is US procedure growth falling to single digits while Hugo and Ottava placements accumulate. That would be the first hard evidence of erosion, and it would cost a notch even if total revenue kept growing on price and mix.
Where the advantage comes from and how long it can last: habit at the console, scale in the rack
The position rests on three sources that reinforce one another: switching costs built into surgeon training, scale in instruments and service, and an accumulated clinical record. None of them is a patent wall. That matters for durability, because organizational advantages decay slowly but they do decay, and the decay usually starts at the edges of the installed base rather than at its center.
Switching costs: Fairly Strong, and they bind hospitals more than patients
The mechanism runs through the surgeon, not the purchasing department.
First, proficiency on a surgical console is learned through repetition. A surgeon needs a run of cases, plus proctoring and simulation time, before a new platform feels safe, and that time comes out of a practice that is already booked. Second, the operating room adapts around a system: room layout, instrument inventories, sterile processing routines, staff credentialing, scheduling templates. Third, a hospital adding a second platform doubles the training and inventory burden on a surgical team it is trying to keep productive, and it must persuade surgeons to give up cases while they climb a new learning curve.
The cost of switching is therefore not the price of a rival robot. It is the disruption of a program that works, borne by people whose time is the scarce resource. That is why entrants need more than a comparable machine; they need a reason for a hospital to run two programs at once.
The reason this rates no higher is that the lock attaches to the institution, not the patient. In most soft-tissue procedures patients do not ask for a specific system; they accept what the surgeon proposes. And the switching cost is highest for a hospital that has never built a robotics service. For one that already has, adding a second platform is cheaper than starting from zero, because the training infrastructure, credentialing process and capital budget already exist. The installed base is not uniformly defended, and the largest, most experienced customers are the most reachable ones for challengers. BTIG's survey work has found no share erosion so far; the structural point is that the direction of travel favors entrants at the margin, even if it takes years to show.
Scale in instruments and service: Strong, though capital is not the barrier
The system sale is the entry ticket; the money is in the consumables each procedure burns and the service contract attached to the machine. Intuitive's fixed costs, which include R&D, clinical trials, manufacturing tooling, field service and a field organization that supports surgeons in the operating room, spread across an installed base above 12,000 systems and a rising procedure count. Each additional procedure adds instrument revenue at a high incremental margin, which is why a 66% gross margin and a 29% operating margin survive in a business that spends heavily on engineering.
Scale works through three channels. Higher instrument volumes per design lower unit cost and improve supply reliability. A dense installed base lowers the cost of a service call, because a technician covers more accounts per day and parts sit closer to the point of use. And a larger revenue pool funds the next round of clinical evidence and product development without straining the balance sheet: free cash flow of $2.49 billion in fiscal 2025 covered a $2.36 billion financing outflow and still left the cash balance higher than it started.
The limit matters. Medtronic and Johnson & Johnson can absorb a decade of losses in robotic surgery without noticing, so access to capital is not what protects Intuitive. Scale protects it through cost per unit and service density, and those edges are real but narrower than the size of the balance sheet suggests. Scale: Strong.
Clinical evidence and approval breadth: Moderate
An FDA clearance no longer separates winners from losers; three soft-tissue systems hold one. What stays scarce is the record behind the clearance: indication-by-indication clinical data, published outcomes, surgeon training pathways and reimbursement precedent that hospitals and payers rely on. A rival contesting a new procedure needs its own evidence, and the incumbent's library compounds with every study. That is why Intuitive's push into broader general surgery proceeds one indication at a time, and why challengers must climb the same ladder from a standing start.
It rates only Moderate because regulators do not defend incumbents. The de novo pathway Ottava used shows how a well-funded entrant can clear the agency and then build evidence with commercial cases. Approval costs years; it does not stop entry. Evidence and approvals: Moderate.
What could erode it: laparoscopy above, price competition abroad
The substitute that matters most is not another robot. It is conventional laparoscopy, which many surgeons already perform well at a fraction of the capital and per-case cost. Robotic surgery wins clearly where dexterity, visualization and ergonomics change the outcome or the surgeon's stamina, with prostatectomy the clearest example. Where the clinical gain is marginal, the hospital carries the capital cost and the payer sees little reason to pay a premium, so laparoscopy sets a ceiling on pricing and on how many procedures convert. That explains why Intuitive keeps funding procedure-by-procedure evidence instead of raising prices on the base it already has.
Geography is the second soft spot. Chinese vendors such as MicroPort MedBot, Kangduo and Toumai compete on price and local standing, and Oppenheimer and Needham both expect the meaningful challenge to arrive outside the US. If those systems prove adequate in emerging markets, Intuitive's international growth may come at lower prices and thinner margins than the US business it was modeled on. The same logic reaches ambulatory surgery centers at home, where a cheaper modular system may fit the economics better than a full da Vinci suite.
Taken together, the moat looks durable in its core US hospital base for roughly the next decade and thinner at the edges: price-sensitive foreign markets, low-acuity procedures, and sites where capital cost dominates the decision. The number to watch is procedure growth per installed system. One quarter proves nothing, but two or three years of decelerating utilization alongside rising Hugo and Ottava placements would say that Intuitive's customers are paying down the switching costs it depends on.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Comparison and summaryHow Intuitive Surgical Inc compares with its closest rivals, and our moat rating
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Intuitive Surgical Inc
Intuitive Surgical Inc
Business, moat and key questions
Open company page